Dementia of the Alzheimer Type: the Drug Treatment Debate

Size: px
Start display at page:

Download "Dementia of the Alzheimer Type: the Drug Treatment Debate"

Transcription

1 Dementia of the Alzheimer Type: the Drug Treatment Debate

2 I have no financial conflict of interest. Many years ago I was given a trip to San Fran and taught to use a slide set from the drug company. I proposed some changes. I never heard from them again.

3 Imagine an elderly person who has dementia of the Alzheimer type. What goals of treatment would be meaningful to patient or caregiver and would justify much expense and some risk?

4 Goals A better life for patient? Disease stabilization? A better life for caregiver? Less expense? Psychometric testing?

5 Does the patient s quality of life improve?

6 Quality of Life, donepezil trials Four trials measure this for patients One favors donepezil at low dose, not high dose One favors placebo Mean difference 10 points The scale is 350 points.

7 No significant differences were seen between donepezil and placebo in behavioural and psychological symptoms, carer psychopathology, formal care costs, unpaid caregiver time, adverse events or deaths, or between 5mg and 10 mg donepezil. Courtney Lancet 2004

8 Does the disease stabilize?

9

10

11 drug placebo

12 Evidence is insufficient to support the use of pharmaceutical agents or dietary supplements to prevent cognitive decline or Alzheimer s disease. Preventing AD and cognitive decline Statement.pdf

13 The Package Insert.

14 Despite intensive laboratory and clinical research over three decades, an effective treatment to delay the onset and progression of Alzheimer's disease is not at hand. Selkoe, DJ Preventing AD Science; 21 Sept 2012

15 No significant benefits were seen with donepezil compared with placebo in institutionalisations (42% vs. 44% at 3 years; p=0.4) or progression of disability (58% vs. 59% at 3 years; p=0.4). Courtney Lancet 2004

16 Use of donepezil by AD patients resulted significant delays in NHP. Geldmacher JAGS 2003

17 Given that treatment with a ChEI is currently recommended as the standard of care for AD patients, conducting such a study (a proper RCT) would not be ethical. Geldmacher JAGS 2003

18

19 How about cognitive testing?

20 Cognition average 0.8 MMSE (mini-mental state examination) points better (95% CI ; p<0.0001) and functionality 1.0 BADLS points better ( ; p<0.0001) with donepezil over the first 2 years. Courtney Lancet 2004

21 MMSE favored treatment in 7 of 9 trials in which it was measured. All differences less than 2 points

22 CIBIC Average difference 0.3 to 0.5 Cummings NEJ 2005 Minimum change that can be scored: 1point

23 ADAS cog favored donepezil in all 6 trials in which it was measured. All differences less than 4 points

24 ADAS-cog About 1 additional patient in 10 had a 4 point improvement on drug compared to placebo. Cummings NEJ 2004

25 How about Behavioral Disturbances?

26 NPI-NH no significant differences observed between the groups at any assessment Physical Self-Maintenance Score and MMSE not different at study s end (24 months) CDR-SB less than 1 point difference Tariot JAGS 2001

27 Pts treated with donepezil maintained or improved in cognition and overall dementia severity Tariot JAGS 2001

28 NPI Placebo Donep Baseline 5 months

29 At the very least, the data in this trial demonstrate that cognition and overall dementia severity are maintained for 6 months. Tariot JAGS 2001

30 NPI Placebo Donep Baseline 5 months

31 May 29, 2003: We found the weapons of mass destruction. We found biological laboratories. November 12, 2005: We do not torture." October 25, 2006: Absolutely, we're winning.

32 In summary, benefits of donepezil treatment on cognition and overall dementia severity were evident in these NH patients. Tariot JAGS 2001

33 NPI Placebo Donep Baseline 5 months

34

35 An RCT without Pharma guidance There was no significant difference between the effects of donepezil and those of placebo on the basis of the change in CMAI scores from baseline to 12 weeks

36 There were also no significant differences between the placebo and donepezil groups in scores for the Neuropsychiatric Inventory, the Neuropsychiatric Inventory Caregiver Distress Scale, or the Clinician's Global Impression of Change.

37 CONCLUSIONS: In this 12- week trial, donepezil was not more effective than placebo in treating agitation in patients with Alzheimer's disease. Howard RJ N Engl J Med 2007

38 Goals A better life for patient? Disease stabilization? A better life for caregiver? Less expense? Psychometric testing?

39

40 How did we get here? Sales of these drugs are in the billions.

41 The talking chihuahua (Why were we in line at Taco Bell?) Chihuahua Number 1

42 ChEIs are approved for treatment of mild-tomoderate AD and should be considered as a standard of care for patients with AD. refs 50,51 Cummings NEJ 2004

43 Practice recommendations Pharmacologic treatment of AD. Cholinesterase inhibitors should be considered in patients with mild to moderate AD (Standard), although studies suggest a small average degree of benefit. Doody, R,S. Practice Parameter: Management of dementia American Academy of Neurology 2001

44 Physicians may consider a trial of either of these agents for patients with mild to moderate AD. Small 1997 JAMA What are these two drugs? Tacrine and donepezil (1 trial cited)

45 Recommendations for the use of ChEIs do not seem to be evidence-based. Benefits on rating scales were minimal The methodological quality of the available trials was poor. Kaduskiewicz BMJ 2005

46 Chihuahua Number 2

47 Doctors and caregivers need to be educated that, in the same way as the actual benefits of treating hypertension or hyperlipidemia are seen only after years of treatment treatment of AD with donepezil needs to be maintained to see important long-term benefits. Geldmacher 2001

48

49 And there are many chihuahuas.

50 Carefully manicured evidence

51 Abstract First in Results Final Discussion First First of concluding para Final

52 Rogers 1998a Abstract 1 2 Discussion 1 efficacious treating symptoms 2 3

53 Rogers 1998b Abstract 1 2 efficacious treating symptoms Discussion 1 2 3

54 Burns 1999 Abstract 1 2 Discussion 1 2 efficacious treating symptoms 3

55 Rogers 1998 Abstract 1 2 well-tolerated and efficacious Discussion 1 2 well-tolerated and efficacious 3

56 Burns 1999 Abstract 1 2 effective and well tolerated Discussion 1 2 well-tolerated and efficacious 3 effective and well tolerated

57 Homma 2000 Abstract 1 2 Discussion 1 effective and well-tolerated 2 3

58 Winblad 2001 Abstract 1 2 well tolerated and effective Discussion 1 2 3

59 Greenberg 2000 Abstract 1 2 modestly improves cognition Discussion 1 modest beneficial effect 2 small beneficial effect 3

60 Renting an office at the FDA

61 What would you do if your blockbuster was going off patent? And it would become available in 5 mg and 10 mg tablets generically?

62 Aricept 23? The current regulatory standard requires that the effectiveness of a treatment for Alzheimer s Disease be demonstrated on both a cognitive and a global (or functional) primary efficacy measure

63 10 23 p SIB (100-point scale) CIBIC plus

64 Medical Reviewer I recommend that this application, which seeks the approval of Aricept in a new dose strength of 23 mg administered once daily, for the treatment of moderate to severe dementia of the Alzheimer s type not be approved.

65 Statistical reviewer Unless there is some compelling prior reason to believe that there is a dose response between 10 mg IR (immediate release) and 23 mg SR (suspended release), the data from this trial does not seem to provide enough support for the efficacy of the 23 mg SR formulation.

66 Division Director Not only was there no statistical significance between the treatments on the primary measure of overall functioning, but there was a clear lack of significance on another accepted measure, the ADCS-ADL [a secondary endpoint].

67 There is a clear increase in the incidence of adverse events on the 23 mg dose compared to the 10 mg dose ; These are not trivial events in these patients; these could lead to significant morbidities and even increased mortality ;

68 These events are of particular concern, given that these patients had all been receiving treatment with 10 mg once a day for at least three months. That is, even though patients had been tolerating (more or less) a dose of 10 mg for three months, the increase to 23 mg was clearly accompanied by a significant increase in the incidence of these events

69 Division Director Then he approved it.

70 Schwartz L, Woloshin S. BMJ. Not so stories Public Citizen Petition. g1950

71 HARMS

72 ChEI s and syncope Cohort study 20,000 patients on drug, 60,000 not Increased risks of Syncope Pacers Hip fracture Gill S. Arch Intern Med 2009

73 Cholinesterase Inhibitors and Hospitalization for Bradycardia: A Population-Based Study More than doubled. Laura Y. Park-Wyllie September 2009 PLoS.

74 Do I have time to tell you about the Geldmacher study?

75 Far too large a section of the treatment of disease is today controlled by the big manufacturing pharmacists, who have enslaved us in a plausible pseudoscience. Osler, 1909

Known as both a thief and murderer,

Known as both a thief and murderer, &A Dementia Drugs: When Should They Be Stopped? Ron Keren, MD, FRCPC As presented at the University of Toronto s Primary Care Conference, Toronto, Ontario (May 25) Known as both a thief and murderer, Alzheimer

More information

Month/Year of Review: September 2013 Date of Last Review: February 2012

Month/Year of Review: September 2013 Date of Last Review: February 2012 Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights

More information

Rational Medication Use in Dementia

Rational Medication Use in Dementia Rational Medication Use in Dementia Stephen Thielke sthielke@u.washington.edu (206) 764 2815 I have no conflicts of interest to report. I am an employee of the federal government. The opinions in this

More information

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a

More information

Literature Scan: Alzheimer s Drugs

Literature Scan: Alzheimer s Drugs Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Neurocognitive Disorders Research to Emerging Therapies

Neurocognitive Disorders Research to Emerging Therapies Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Atri A, Frölich L, Ballard C, et al. Effect of idalopirdine as adjunct to cholinesterase inhibitors on in cognition in patients with Alzheimer disease: three randomized clinical

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111) Appraisal

More information

Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease

Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top

More information

SUBMISSION TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE MULTIPLE TECHNOLOGY APPRAISAL (MTA)

SUBMISSION TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE MULTIPLE TECHNOLOGY APPRAISAL (MTA) ARICEPT (DONEPEZIL) SUBMISSION TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE MULTIPLE TECHNOLOGY APPRAISAL (MTA) Prepared by: Eisai Ltd Mosquito Way, Hatfield, Hertfordshire, AL10 9SN Company

More information

The place for treatments of associated neuropsychiatric and other symptoms

The place for treatments of associated neuropsychiatric and other symptoms The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public

More information

Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA

Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer

More information

Drug Update. Treatments for Cognitive Impairment in the Older Adult. William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle

Drug Update. Treatments for Cognitive Impairment in the Older Adult. William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle Drug Update Treatments for Cognitive Impairment in the Older Adult William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle Current Drug Treatments for Alzheimer s Disease Cholinesterase Inhibitors:

More information

Recommendations on Screening for Cognitive Impairment in Older Adults 2015

Recommendations on Screening for Cognitive Impairment in Older Adults 2015 Recommendations on Screening for Cognitive Impairment in Older Adults 2015 Canadian Task Force on Preventive Health Care (CTFPHC) Putting Prevention into Practice Canadian Task Force on Preventive Health

More information

Medications for treating people with dementia: summary of evidence on cost-effectiveness

Medications for treating people with dementia: summary of evidence on cost-effectiveness Medications for treating people with dementia: summary of evidence on cost-effectiveness Martin Knapp, A-La Park and Alistair Burns PSSRU, London School of Economics and Political Science v4 23 July 2017

More information

Alzheimer Disease Agents Drug Class Prior Authorization Protocol

Alzheimer Disease Agents Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Alzheimer Disease Agents Drug Class Prior Authorization Protocol This policy has been developed through review

More information

Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217

Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217 NICE 2017. All rights reserved.

More information

LTC Research Influencing Practice

LTC Research Influencing Practice LTC Research Influencing Practice David A. Nace, MD, MPH Division of Geriatric Medicine naceda@upmc.edu PGS Clinical Update April 6, 2017 Conflicts of Interest Dr. Nace does not have any current conflicts

More information

PMDA Considerations for Outcome Assessments

PMDA Considerations for Outcome Assessments PMDA Considerations for Outcome Assessments Keiju Motohashi Office of New Drug II Pharmaceuticals and Medical Devices Agency/ The University of Tokyo Hospital Disclaimer The views and opinions expressed

More information

Donepezil, (R,S)-1-benzyl-4[(5,6 dimethoxy-1-indanon)- Update on Alzheimer Drugs (Donepezil) ORIGINAL ARTICLE. Rachelle Smith Doody, MD, PhD

Donepezil, (R,S)-1-benzyl-4[(5,6 dimethoxy-1-indanon)- Update on Alzheimer Drugs (Donepezil) ORIGINAL ARTICLE. Rachelle Smith Doody, MD, PhD ORIGINAL ARTICLE Update on Alzheimer Drugs (Donepezil) Rachelle Smith Doody, MD, PhD Background: Several clinical trials have been conducted over a period of many years reporting the benefits of donepezil

More information

Medication Treatments for Dementia. Stephen Thielke

Medication Treatments for Dementia. Stephen Thielke Medication Treatments for Dementia Stephen Thielke Treatment is a MORAL decision. Facts can help you determine HOW to accomplish something. Facts cannot tell you WHAT YOU WANT to accomplish. Dementia Meds

More information

Cholinesterase inhibitors for Alzheimer s disease (Review)

Cholinesterase inhibitors for Alzheimer s disease (Review) Birks J This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2008, Issue 3 http://www.thecochranelibrary.com 1 T A B L E O

More information

Managing agitation in dementia using non-pharmacological therapies

Managing agitation in dementia using non-pharmacological therapies Managing agitation in dementia using non-pharmacological therapies Gill Livingston Lynsey Kelly, Elanor Lewis-Holmes, Gianluca Baio, Rumana Omar, Stephen Morris, Nishma Patel, Cornelius Katona, Claudia

More information

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA 111)

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA 111) National Institute for Health and Clinical Excellence Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA 111) Response

More information

Executive Summary. The Royal Australasian College of Physicians July 2012 Page 1 of 5

Executive Summary. The Royal Australasian College of Physicians July 2012 Page 1 of 5 PBAC Review of Pharmaceutical Benefits Scheme anti-dementia drugs to treat Alzheimer s disease Submission by The Royal Australasian College of Physicians July 2012 The Royal Australasian College of Physicians

More information

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY

More information

Trial Designs and Outcomes to Monitor Novel Therapeutics in Alzheimer s Disease

Trial Designs and Outcomes to Monitor Novel Therapeutics in Alzheimer s Disease 2 Trial Designs and Outcomes to Monitor Novel Therapeutics in Alzheimer s Disease Serge Gauthier Introduction The various etiological hypotheses for Alzheimer s disease (AD) need to be tested in patients

More information

Gary Wieczorek, Associate Director, Regulatory Affairs Eisai Medical Research Inc. 300 Tice Blvd Woodcliff Lake, NJ 07677

Gary Wieczorek, Associate Director, Regulatory Affairs Eisai Medical Research Inc. 300 Tice Blvd Woodcliff Lake, NJ 07677 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Gary Wieczorek, Associate Director, Regulatory Affairs 300 Tice

More information

The most common cause of dementia in the elderly is. Cholinesterase Inhibitors in the Treatment of Dementia REVIEW ARTICLE. Jay M.

The most common cause of dementia in the elderly is. Cholinesterase Inhibitors in the Treatment of Dementia REVIEW ARTICLE. Jay M. Cholinesterase Inhibitors in the Treatment of Dementia Jay M. Ellis, DO Dementia associated with probable Alzheimer s disease (AD) is one of the most common types of dementia. Patients with AD often have

More information

ALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health

ALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health ALZHEIMER S DISEASE OVERVIEW Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health Prevalence AD: DEMOGRAPHY AND CLINICAL FEATURES Risk and protective factors Clinical features and

More information

Management of cognition and function: new results from the clinical trials programme of Aricept (donepezil HCl)

Management of cognition and function: new results from the clinical trials programme of Aricept (donepezil HCl) International Journal of Neuropsychopharmacology (2000), 3 (Supplement 2), S13 S20. Copyright 2000 CINP Management of cognition and function: new results from the clinical trials programme of Aricept (donepezil

More information

Title of Study: Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Title of Study: Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil SYNOPSIS Name of Sponsor/Company Name of Finished Product REMINYL Name of Active Ingredient(s) Galantamine hydrobromide Issue Date: 18 October 2013 Protocol No.: Title of Study: Evaluation of Efficacy

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized controlled trial. JAMA. doi:10.1001/jama.2014.93 eappendix.

More information

Corporate Presentation August 6, 2015

Corporate Presentation August 6, 2015 Corporate Presentation August 6, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events

More information

Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-alzheimer s dementia

Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-alzheimer s dementia STEER 2002; Vol 2: No.2 Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-alzheimer s dementia Bunmi Fajemisin Evidence search date: November 2001 www.signpoststeer.org

More information

MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS

MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS A REALITY CHECK reality check Noun informal an occasion on which one is reminded of the state of things in the real world. ROBERT LACOSTE, MD MEDICAL DIRECTOR,

More information

Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches

Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Andrea Iaboni, MD, DPhil, FRCPC Toronto Rehab Institute, UHN Learning objectives Recognize

More information

Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University

Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University Design of trials in DLB and PDD What has been learnt from previous trials in these indications and other dementias? Overview

More information

Disclosure. I have no conflict of interest with respect to this talk. I am on the formulary committee for a large insurance company.

Disclosure. I have no conflict of interest with respect to this talk. I am on the formulary committee for a large insurance company. CHOOSING WISELY FOR VULNERABLE ELDERS DECEMBER 11, 2014 TOM FINUCANE Disclosure I have no conflict of interest with respect to this talk. I am on the formulary committee for a large insurance company.

More information

CHOOSING WISELY FOR VULNERABLE ELDERS DECEMBER 11, 2014 TOM FINUCANE

CHOOSING WISELY FOR VULNERABLE ELDERS DECEMBER 11, 2014 TOM FINUCANE CHOOSING WISELY FOR VULNERABLE ELDERS DECEMBER 11, 2014 TOM FINUCANE Disclosure I have no conflict of interest with respect to this talk. I am on the formulary committee for a large insurance company.

More information

Neuropsychiatric Syndromes

Neuropsychiatric Syndromes Neuropsychiatric Syndromes Susan Czapiewski,MD VAHCS December 10, 2015 Dr. Czapiewski has indicated no potential conflict of interest to this presentation. She does intend to discuss the off-label use

More information

8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research

8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event

More information

Follow this and additional works at: Part of the Nervous System Diseases Commons

Follow this and additional works at:  Part of the Nervous System Diseases Commons Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is 30 ml Cerebrolysin a Safe and Effective

More information

Evidence-based pharmacotherapy of Alzheimer s disease

Evidence-based pharmacotherapy of Alzheimer s disease International Journal of Neuropsychopharmacology (2004), 7, 351 369. Copyright f 2004 CINP DOI: 10.1017/S1461145704004444 Evidence-based pharmacotherapy of Alzheimer s disease SPECIAL SERIES John Grimley

More information

Psychological therapies for people with dementia who have associated depression [New 2015].

Psychological therapies for people with dementia who have associated depression [New 2015]. Psychological therapies for people with dementia who have associated depression [New 2015]. SCOPING QUESTION: For people with dementia and comorbid depression, do psychological interventions (including

More information

Alzheimer s & Dementia Intervention Program A Case Review

Alzheimer s & Dementia Intervention Program A Case Review Alzheimer s & Dementia Intervention Program A Case Review Alzheimer s Australia 15 th National Conference May 15 th, 2013 Early dementia symptoms, no worries? Patricia and her daughter both knew something

More information

Shire Pharmaceuticals/Johnson & Johnson 16 December 2005

Shire Pharmaceuticals/Johnson & Johnson 16 December 2005 Shire Pharmaceuticals/Johnson & Johnson 16 December 2005 Comments on Addenda to MRC report on clinical efficacy and NICE Technical Report 2; Drugs for the Treatment of Alzheimer s Disease (review) Executive

More information

Alzheimer Clinical Trials: History and Lessons

Alzheimer Clinical Trials: History and Lessons Alzheimer Clinical Trials: History and Lessons Jeffrey Cummings, MD, ScD Center for Neurodegeneration and Translational Neuroscience Cleveland Clinic Lou Ruvo Center for Brain Health Disclosures Dr. Cummings

More information

Hisanori Kobayashi, Takashi Ohnishi, Ryoko Nakagawa and Kazutake Yoshizawa

Hisanori Kobayashi, Takashi Ohnishi, Ryoko Nakagawa and Kazutake Yoshizawa RESEARCH ARTICLE The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer s disease: a Bayesian network meta-analysis Hisanori Kobayashi, Takashi Ohnishi,

More information

Conflicts of interest

Conflicts of interest Conflicts of interest Peter C Gøtzsche Director and Professor Nordic Cochrane Centre I have no conflicts of interest Our drug epidemic 8 mio daily doses in Denmark; 5.5 mio inhabitants One of eight get

More information

September 30, Eric BASTINGS, MD. Acting Director Division of Neurology Products (DNP) Center for Drug Evaluation and Research (CDER)

September 30, Eric BASTINGS, MD. Acting Director Division of Neurology Products (DNP) Center for Drug Evaluation and Research (CDER) ISCTM Autumn Conference Options and methods to improve cognitive assessment in clinical trials of AD and its precursors September 30, 2013 Eric BASTINGS, MD Acting Director Division of Neurology Products

More information

Drug Class Review Alzheimer s Drugs

Drug Class Review Alzheimer s Drugs Drug Class Review Alzheimer s Drugs Preliminary Scan Report #5 August 2014 Last Report: June 2006 The purpose of reports is to make available information regarding the comparative clinical effectiveness

More information

November 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by

November 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Major Neurocognitive Disorder: The Beginning and the End. Making the Diagnosis and Addressing Distressing Behavior W. Vaughn McCall, MD,

More information

Issues to Consider in the Clinical Evaluation and Development of Drugs for Alzheimer s Disease. The University of Tokyo Hospital

Issues to Consider in the Clinical Evaluation and Development of Drugs for Alzheimer s Disease. The University of Tokyo Hospital Project to Promote the Development of Innovative Pharmaceuticals, Medical Devices, and Regenerative Medical Products (Ministry of Health, Labour, and Welfare) Regulatory Science Research for the Establishment

More information

NEUROPSYCHOMETRIC TESTS

NEUROPSYCHOMETRIC TESTS NEUROPSYCHOMETRIC TESTS CAMCOG It is the Cognitive section of Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) The measure assesses orientation, language, memory, praxis, attention, abstract

More information

Dementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018

Dementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018 Dementia NICE Guidelines Update Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018 How NICE guidelines are reviewed Multidisciplinary guideline committee established Review

More information

Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease. Summary

Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease. Summary Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease Summary Mai 17 th 2017 Background Alzheimer s disease is a serious neurocognitive disorder which is characterized

More information

Evidence-Based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine in People with Dementia

Evidence-Based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine in People with Dementia Evidence-Based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine in People with Dementia ADI 2018, Chicago FACULTY OF MEDICINE Dr Emily Reeve NHMRC Cognitive Decline

More information

FROM THE ALZHEIMER S ASSOCIATION INTERNATIONAL CONFERENCE 2018 NEW RESEARCH FOCUSES ON TREATING NON-COGNITIVE SYMPTOMS OF PEOPLE WITH DEMENTIA

FROM THE ALZHEIMER S ASSOCIATION INTERNATIONAL CONFERENCE 2018 NEW RESEARCH FOCUSES ON TREATING NON-COGNITIVE SYMPTOMS OF PEOPLE WITH DEMENTIA CONTACT: Alzheimer s Association AAIC Press Office, 312-949-8710, aaicmedia@alz.org Niles Frantz, Alzheimer s Association, 312-335-5777, niles.frantz@alz.org FROM THE ALZHEIMER S ASSOCIATION INTERNATIONAL

More information

Recommendations For the Use of Donepezil

Recommendations For the Use of Donepezil Recommendations For the Use of Donepezil The trial of donepezil in patients with mild to moderate dementia due to probable AD was one recommendation made by the Canadian Consensus Conference on Dementia.

More information

The Place for Treatments of Associated Neuropsychiatric and Other Symptoms in Alzheimer s Disease and Other Dementias

The Place for Treatments of Associated Neuropsychiatric and Other Symptoms in Alzheimer s Disease and Other Dementias The Place for Treatments of Associated Neuropsychiatric and Other Symptoms in Alzheimer s Disease and Other Dementias The Patient and Carers Perspective Mary-Frances Morris, Trustee, Alzheimer Scotland.

More information

Trial clinici nell anziano: efficacy or effectiveness?

Trial clinici nell anziano: efficacy or effectiveness? LA SPERIMENTAZIONE FARMACOLOGICA CLINICA IN ETÀ GERIATRICA Trial clinici nell anziano: efficacy or effectiveness? Graziano Onder Fondazione Universitaria Policlinico A. Gemelli Università Cattolica del

More information

Mild Cognitive Impairment Symposium January 19 and 20, 2013

Mild Cognitive Impairment Symposium January 19 and 20, 2013 Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment

More information

Review Article Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate, and Severe Alzheimer s Disease

Review Article Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate, and Severe Alzheimer s Disease International Alzheimer s Disease Volume 2012, Article ID 707468, 4 pages doi:10.1155/2012/707468 Review Article Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate,

More information

Antipsychotic Medications

Antipsychotic Medications TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood

More information

Drug Class Review on Alzheimer s Drugs

Drug Class Review on Alzheimer s Drugs Drug Class Review on Alzheimer s Drugs April 2005 The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical

More information

A pan-european study on outcome measures for psychosocial intervention research in dementia

A pan-european study on outcome measures for psychosocial intervention research in dementia A pan-european study on outcome measures for psychosocial intervention research in dementia CHATTAT Rabih, MONIZ-COOK Esme, WOODS Bob, and members of the INTERDEM JPND outcomes working group 26 th Alzheimer

More information

CTFPHC Working Group Members:

CTFPHC Working Group Members: Cognitive Impairment - Guideline Presentation Speaker deck OVERVIEW We will review the following: 1. Background on Cognitive Impairment 2. Methods of the CTFPHC 3. Recommendations and Key Findings 4. Implementation

More information

SHARED CARE PROTOCOL CHOLINESTERASE INHIBITORS IN ALZHEIMER S DEMENTIA

SHARED CARE PROTOCOL CHOLINESTERASE INHIBITORS IN ALZHEIMER S DEMENTIA SHARED CARE PROTOCOL CHOLINESTERASE INHIBITORS IN ALZHEIMER S DEMENTIA Introduction Alzheimer s disease is the most common cause of dementia. It is characterised by an insidious onset of global mental

More information

Summary of funded Dementia Research Projects

Summary of funded Dementia Research Projects Summary of funded Dementia Research Projects Health Services and Delivery Research (HS&DR) Programme: HS&DR 11/2000/05 The detection and management of pain in patients with dementia in acute care settings:

More information

Management of the Acutely Agitated Long Term Care Patient

Management of the Acutely Agitated Long Term Care Patient Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia

More information

ARICEPT and ARICEPT-D contain the active ingredient donepezil hydrochloride (AAN).

ARICEPT and ARICEPT-D contain the active ingredient donepezil hydrochloride (AAN). PRODUCT INFORMATION ARICEPT, ARICEPT -D (donepezil hydrochloride) NAME OF THE MEDICINE ARICEPT and ARICEPT-D contain the active ingredient donepezil hydrochloride (AAN). The structural formula of donepezil

More information

As people age, changes to the structure

As people age, changes to the structure CMAJ Guidelines CME Recommendations on screening for cognitive impairment in older adults Canadian Task Force on Preventive Health Care* CMAJ podcasts: author interview at https://soundcloud.com/cmajpodcasts/141165-guide

More information

C holinomimetic drugs constitute the first line of treatment

C holinomimetic drugs constitute the first line of treatment 310 PAPER Cholinesterase inhibitor treatment alters the natural history of Alzheimer s disease O L Lopez, J T Becker, S Wisniewski, J Saxton, D I Kaufer, S T DeKosky... See end of article for authors affiliations...

More information

Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia

Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Hull & East Riding Prescribing Committee Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)

More information

Rational Drug Used For Cognitive Treatment of Alzheimer Disease And Related Dementia

Rational Drug Used For Cognitive Treatment of Alzheimer Disease And Related Dementia Spectrum of AD Rational Drug Used For Cognitive Treatment of Alzheimer Disease And Related Dementia Assoc.Prof. Vorapun Senanarong, BSc., MD., DTM&H(London), FRCP(London) MCI, mild cognitive Impairment

More information

COGNOS. Care for people with Cognitive dysfunction A National Observational Study. Professor Dr Jan De Lepeleire COGNOS members

COGNOS. Care for people with Cognitive dysfunction A National Observational Study. Professor Dr Jan De Lepeleire COGNOS members COGNOS Care for people with Cognitive dysfunction A National Observational Study Professor Dr Jan De Lepeleire COGNOS members Luxembourg Alzheimer Europe 2010 The Careplan in Belgium Requirements for reimbursement

More information

11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease

11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease Disclosures Behavioral Management of Persons with Alzheimer s Disease Wisconsin Association of Medical Directors November 17, 2016 Art Walaszek, M.D. Professor of Psychiatry UW School of Medicine & Public

More information

Although cholinesterase inhibitors (ChEIs) and memantine

Although cholinesterase inhibitors (ChEIs) and memantine High-dose donepezil or memantine: Next step for Alzheimer s disease? Larger dosages may benefit patients who have maxed out existing therapies Indrapal Singh, MD Assistant Professor Department of Geriatric

More information

It is only in the past decade that pharmacologic

It is only in the past decade that pharmacologic IS THERE TREATMENT FOR ALZHEIMER S DISEASE? Gary M. Levin, PharmD, BCPP, FCCP * ABSTRACT There are now 5 approved drugs for the primary symptoms of Alzheimer s disease (AD), 4 of which inhibit acetylcholinesterase

More information

Drugs for dementia: the first year

Drugs for dementia: the first year The Ulster Medical Journal, Volume 69, No. 2, pp. 123-127, November 2000. Drugs for dementia: the first year An audit of prescribing practice G McGirr, S A Compton Accepted 12 September 2000 SUMMARY In

More information

ANTIOXIDANT SUPPLEMENTS IN ALZHEIMER S DEMENTIA AND MILD COGNITIVE IMPAIRMENT: A SYSTEMATIC REVIEW

ANTIOXIDANT SUPPLEMENTS IN ALZHEIMER S DEMENTIA AND MILD COGNITIVE IMPAIRMENT: A SYSTEMATIC REVIEW Journal of Aging Research & Clinical Practice Volume 6, 2017 J Aging Res Clin Practice 2017;6:1-8 Published online December 1, 2016, http://dx.doi.org/10.14283/jarcp.2016.121 ANTIOXIDANT SUPPLEMENTS IN

More information

Management of Agitation in Dementia. Kimberly Triplett Ferguson, MS4

Management of Agitation in Dementia. Kimberly Triplett Ferguson, MS4 Management of Agitation in Dementia Kimberly Triplett Ferguson, MS4 Objectives 1. Review recommended evaluation of agitated patients with dementia. 2. Discuss evidence concerning nonpharmacologic management.

More information

Misuse of Bisphosphonates. Dr Rukhsana Parvin Associate Professor Department of Medicine Enam Medical College & Hospital

Misuse of Bisphosphonates. Dr Rukhsana Parvin Associate Professor Department of Medicine Enam Medical College & Hospital Misuse of Bisphosphonates Dr Rukhsana Parvin Associate Professor Department of Medicine Enam Medical College & Hospital Introduction Bisphosphonates are chemically stable analogues of pyrophosphate compounds.

More information

November 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by

November 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Treatment Targets in Alzheimer s Disease W. Vaughn McCall, MD, MS Professor and Case Distinguished University Chairman Department of Psychiatry

More information

Draft for Consultation

Draft for Consultation Draft for Consultation Screening for dementia: Can screening bring benefits to those with unrecognised dementia, their carers and society? An appraisal against UKNSC criteria A draft report for the UK

More information

Memantine and cholinesterase inhibitor combination therapy for Alzheimer s disease: a systematic review

Memantine and cholinesterase inhibitor combination therapy for Alzheimer s disease: a systematic review Open Access To cite: Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer s disease: a systematic review. BMJ Open 2012;2:e000917. doi:10.1136/ bmjopen-2012-000917

More information

Current Treatments for Dementia and Future Prospects. James Warner St Charles Hospital, London

Current Treatments for Dementia and Future Prospects. James Warner St Charles Hospital, London Current Treatments for Dementia and Future Prospects James Warner St Charles Hospital, London Dementia Cognitive Non-cognitive (BPSD) Memory orientation language other cognitive abilities praxis planning

More information

Personalized Medicine Where Traditional Chinese Medicine and Western Medicine Can Meet

Personalized Medicine Where Traditional Chinese Medicine and Western Medicine Can Meet Personalized Medicine Where Traditional Chinese Medicine and Western Medicine Can Meet Dr. Jean Paul Collet MD, PhD, Prof. - University of British Columbia - Child and Family Research Institute - BC Children

More information

Number of Items. Response Categories. Part V: Specific Behavior Scales-Sleep Scales. Based on past month

Number of Items. Response Categories. Part V: Specific Behavior Scales-Sleep Scales. Based on past month Part V: Specific Behavior Scales-Sleep Scales Based on past month First 4 items ask for time or amount of sleep 41. Pittsburgh Sleep Quality Index (PSQI) Sleep quality Sleep latency Sleep duration Habitual

More information

PRESCRIBING FOR PEOPLE WITH DEMENTIA; SELECTED FINDINGS FROM POMH-UK QUALITY IMPROVEMENT PROGRAMMES (QIPS)

PRESCRIBING FOR PEOPLE WITH DEMENTIA; SELECTED FINDINGS FROM POMH-UK QUALITY IMPROVEMENT PROGRAMMES (QIPS) PRESCRIBING FOR PEOPLE WITH DEMENTIA; SELECTED FINDINGS FROM POMH-UK QUALITY IMPROVEMENT PROGRAMMES (QIPS) The Prescribing Observatory for Mental Health (POMH-UK) is a national initiative to improve the

More information

T he prevalence of Parkinson s disease (PD) is nearly 1% in

T he prevalence of Parkinson s disease (PD) is nearly 1% in 708 PAPER Donepezil for cognitive impairment in Parkinson s disease: a randomised controlled study D Aarsland, K Laake, J P Larsen, C Janvin... See end of article for authors affiliations... Correspondence

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Memantine ER (Namenda XR), galantamine (Razadyne, Razadyne ER) Reference Number: CP.CPA.102 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See

More information

The Rest is Noise. The Promise of ecoa in Increasing Signal Detection

The Rest is Noise. The Promise of ecoa in Increasing Signal Detection Medavante Research White paper The Rest is Noise The Promise of ecoa in Increasing Signal Detection By Christopher Randolph, PhD, ABPP-CN Medical Director of Neuropsychology, Loyola University Medical

More information

NEW ZEALAND DATA SHEET ARICEPT, ARICEPT -D

NEW ZEALAND DATA SHEET ARICEPT, ARICEPT -D NEW ZEALAND DATA SHEET ARICEPT, ARICEPT -D Donepezil hydrochloride 5 mg, 10 mg film-coated tablets 5 mg, 10 mg orally disintegrating tablets Presentation ARICEPT film-coated tablets for oral administration

More information

Assessing and Managing the Patient with Cognitive Decline

Assessing and Managing the Patient with Cognitive Decline Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor

More information

Psychosis and Agitation in Dementia

Psychosis and Agitation in Dementia Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University

More information

Prescribing Framework for Galantamine in the Treatment and Management of Dementia

Prescribing Framework for Galantamine in the Treatment and Management of Dementia Hull & East Riding Prescribing Committee Prescribing Framework for Galantamine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)

More information

Dementia Prevention, Intervention and Care

Dementia Prevention, Intervention and Care Dementia Prevention, Intervention and Care What works and where do we need more research? Demensdagene 07/05/2018 Dr Andrew Sommerlad Wellcome Trust Research Fellow UCL Division of Psychiatry Declaration

More information

10/15/2018. The Role of Palliative Care in the Demented Patient OBJECTIVES SPECIAL THANKS

10/15/2018. The Role of Palliative Care in the Demented Patient OBJECTIVES SPECIAL THANKS The Role of Palliative Care in the Demented Patient OBJECTIVES Describe the Progressive Features of Dementia Bert Knight, MD Medical Director, Palliative Care SPARTANBURG REGIONAL HEALTHCARE SYSTEM Review

More information